These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15208748)

  • 21. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone in the management of disruptive behavior disorders.
    Pandina GJ; Aman MG; Findling RL
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):379-92. PubMed ID: 16958564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
    Martin A; Scahill L; Anderson GM; Aman M; Arnold LE; McCracken J; McDougle CJ; Tierney E; Chuang S; Vitiello B
    Am J Psychiatry; 2004 Jun; 161(6):1125-7. PubMed ID: 15169706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
    Troost PW; Althaus M; Lahuis BE; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):561-73. PubMed ID: 17069545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and long-term safety and tolerability of risperidone in children with autism.
    Aman MG; Arnold LE; McDougle CJ; Vitiello B; Scahill L; Davies M; McCracken JT; Tierney E; Nash PL; Posey DJ; Chuang S; Martin A; Shah B; Gonzalez NM; Swiezy NB; Ritz L; Koenig K; McGough J; Ghuman JK; Lindsay RL
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):869-84. PubMed ID: 16379507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.
    Gebhardt S; Theisen FM; Haberhausen M; Heinzel-Gutenbrunner M; Wehmeier PM; Krieg JC; Kühnau W; Schmidtke J; Remschmidt H; Hebebrand J
    J Clin Pharm Ther; 2010 Apr; 35(2):207-11. PubMed ID: 20456740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone for young children with mood disorders and aggressive behavior.
    Schreier HA
    J Child Adolesc Psychopharmacol; 1998; 8(1):49-59. PubMed ID: 9639079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
    Apiquian R; Fresan A; Ulloa RE; de la Fuente-Sandoval C; Herrera-Estrella M; Vazquez A; Nicolini H; Kapur S
    Neuropsychopharmacology; 2005 Dec; 30(12):2236-44. PubMed ID: 15956984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
    Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
    Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone in pervasive developmental disorders.
    Erickson CA; Stigler KA; Posey DJ; McDougle CJ
    Expert Rev Neurother; 2005 Nov; 5(6):713-9. PubMed ID: 16274329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone side effects.
    Conley RR
    J Clin Psychiatry; 2000; 61 Suppl 8():20-3; discussion 24-5. PubMed ID: 10811239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
    Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
    Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.
    Calarge CA; Ellingrod VL; Zimmerman B; Acion L; Sivitz WI; Schlechte JA
    Psychiatr Genet; 2009 Dec; 19(6):320-7. PubMed ID: 19873684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis.
    Sharma A; Shaw SR
    J Pediatr Health Care; 2012; 26(4):291-9. PubMed ID: 22726714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.